Konruns(SH:603590) Xin Lang Cai Jing·2025-09-12 06:27Core Insights - Kangchen Pharmaceutical's stock price increased by 2.02% on September 12, reaching 54.15 CNY per share, with a total market capitalization of 8.629 billion CNY [1] - The company has seen a year-to-date stock price increase of 136.25%, but has experienced a decline of 4.88% over the last five trading days [1] Financial Performance - For the first half of 2025, Kangchen Pharmaceutical reported a revenue of 461 million CNY, representing a year-on-year growth of 13.79% [2] - The net profit attributable to shareholders for the same period was 91.046 million CNY, reflecting a year-on-year increase of 14.95% [2] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 10.82% to 9,970, while the average number of circulating shares per person increased by 12.14% to 15,771 shares [2] - The company has distributed a total of 437 million CNY in dividends since its A-share listing, with 175 million CNY distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, notable institutional shareholders include Penghua Medical Technology Stock A, which increased its holdings by 354,600 shares, and new entrants such as E Fund Healthcare Industry Mixed A and CITIC Jiantou Medical Reform A [3]